Solid Biosciences (SLDB) COO logs major PSU, RSU awards and tax sell
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Solid Biosciences’ Chief Operating Officer David Howton reported multiple equity compensation events and a related share sale. On January 29, 2026, 79,341 performance stock units vested and converted into common stock, and he received 105,100 new restricted stock units plus an option for 210,200 shares at an exercise price of $6.60 per share, all vesting over four years.
On January 31, 2026, an additional 42,275 restricted stock units vested and converted into common stock. On February 2, 2026, he sold 37,771 shares of common stock at a weighted average price of $6.4369 solely to cover withholding taxes under a pre-established automatic sell-to-cover instruction, and continued to hold 116,753 shares directly afterward.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 37,771 shares ($243,128)
Net Sell
7 txns
Insider
Howton David T
Role
Chief Operating Officer
Sold
37,771 shs ($243K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 37,771 | $6.4369 | $243K |
| Exercise | Restricted Stock Units | 42,275 | $0.00 | -- |
| Exercise | Common Stock | 42,275 | $0.00 | -- |
| Exercise | Performance Stock Units | 79,341 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 210,200 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 105,100 | $0.00 | -- |
| Exercise | Common Stock | 79,341 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 116,753 shares (Direct);
Restricted Stock Units — 126,825 shares (Direct);
Performance Stock Units — 0 shares (Direct);
Employee Stock Option (Right to Buy) — 210,200 shares (Direct)
Footnotes (1)
- Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 169,100 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
FAQ
What insider transactions did SLDB’s COO report on this Form 4?
Solid Biosciences’ COO David Howton reported equity vesting, new grants, and a tax-related share sale. Performance stock units and restricted stock units converted into common stock, he received new options and RSUs, and sold shares only to cover withholding taxes under an automatic instruction.
What new stock options did the Solid Biosciences COO receive?
On January 29, 2026, the COO received an option for 210,200 shares of common stock at a $6.60 exercise price. This option vests over four years, with 25% vesting on the first anniversary and the remainder vesting monthly until the fourth anniversary.
What restricted stock unit (RSU) awards are reported for SLDB’s COO?
The COO holds RSUs that convert one-for-one into common stock. He received 105,100 RSUs on January 29, 2026 that vest in four annual installments, and 169,100 RSUs granted January 31, 2025 vesting 25% on each anniversary of that 2025 grant date.
What performance conditions triggered PSU vesting for SLDB’s COO?
PSUs vested when a predefined non-market, non-financial performance milestone was certified as achieved. On January 29, 2026, the board determined the first milestone under the June 11, 2024 PSU grant was met, causing 25% of the underlying performance stock units to vest and convert.